As CML can reemerge after discontinuation of TKI-treatment despite the availability of various and more potent TKIs, our focus has now shifted to the possibility of TFR and the physiological factors and molecular pathways which may influence this condition. The gene discussed is TFRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.